# Lactobacillus plantarum 299

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-plantarum-299
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Lactobacillus plantarum DSM 9843, LP299V, L. plantarum 299v, DSM 9843, Lactobacillus plantarum strain 299, LP299, Probi Digestis strain

## Overview

Lactobacillus plantarum 299v is a clinically studied probiotic strain that produces lactic acid and adheres to intestinal mucosa via mannose-specific adhesins, competitively excluding pathogens and modulating gut barrier function. Its primary mechanism involves reducing [intestinal permeability](/ingredients/condition/gut-health), suppressing [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α and IL-6, and normalizing bowel motility in irritable bowel syndrome.

## Health Benefits

• Reduces IBS symptoms: In a 214-patient RCT, pain severity decreased by 45.2% vs. 23.3% placebo, with 78.1% rating efficacy as good/excellent (strong evidence, PMID: 22912552)
• Resolves abdominal pain: 100% of IBS patients treated achieved pain resolution vs. 45% placebo in a 40-patient RCT (moderate evidence, PMID: 11711768)
• Improves bloating and colonic fermentation: Significant improvements at weeks 3-4 in IBS patients (moderate evidence, PMID: 12452404)
• May reduce C. difficile recurrence: Fewer recurrences with metronidazole + LP299v (4/11) vs. metronidazole alone (6/9) (preliminary evidence, PMID: 12953945)
• Enhances vascular function: Improved [endothelial function](/ingredients/condition/heart-health) and reduced [inflammation](/ingredients/condition/inflammation) in coronary artery disease patients (preliminary evidence, PMID: 30355158)

## Mechanism of Action

Lactobacillus plantarum 299v adheres to colonic epithelial cells via mannose-specific adhesins, competitively displacing pathogenic bacteria and reinforcing tight-junction proteins including occludin and ZO-1 to reduce [intestinal permeability](/ingredients/condition/gut-health). It downregulates NF-κB signaling, decreasing production of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s TNF-α, IL-6, and IL-1β while promoting anti-inflammatory IL-10 secretion from regulatory T cells. The strain also produces short-chain fatty acids, particularly butyrate, which serve as fuel for colonocytes and further stabilize the mucosal barrier.

## Clinical Summary

A 214-patient randomized controlled trial (PMID: 22912552) demonstrated that Lactobacillus plantarum 299v reduced IBS pain severity by 45.2% compared to 23.3% in the placebo group, with 78.1% of treated patients rating efficacy as good or excellent, representing strong evidence for symptom relief. A smaller 40-patient RCT showed 100% abdominal pain resolution in treated IBS patients versus 45% in the placebo arm, though the modest sample size warrants moderate confidence in this finding. Evidence is strongest for IBS-related abdominal pain and bloating, with less robust data for diarrhea-predominant subtypes and conditions outside the gastrointestinal tract. Overall, the clinical profile of this strain is among the most extensively validated of any single [probiotic](/ingredients/condition/gut-health) strain in gastrointestinal research.

## Nutritional Profile

Lactobacillus plantarum 299 is a viable [probiotic](/ingredients/condition/gut-health) bacterium, not a significant source of macronutrients or micronutrients in conventional dietary terms. Typical therapeutic doses range from 5×10⁹ to 10×10⁹ CFU (colony-forming units) per serving, as used in clinical studies (PMID: 22912552). As a bacterial organism, each cell contributes negligible caloric value (<1 kcal per dose). Bioactive compounds of note include: cell wall components such as lipoteichoic acid and peptidoglycan fragments, which interact with host toll-like receptors (TLR-2) to modulate immune signaling; surface-layer proteins (Slp) that facilitate adhesion to intestinal epithelial mannose receptors; and bacteriocin-like inhibitory substances (BLIS) that confer competitive exclusion against pathogens. L. plantarum 299 produces short-chain fatty acids (SCFAs) — primarily lactic acid (D- and L-isomers), with minor acetic acid production — during fermentation of dietary substrates in the colon, contributing to luminal pH reduction and intestinal barrier support. The strain produces B-group vitamins during [metabolism](/ingredients/condition/weight-management), including folate (B9) and riboflavin (B2), though quantities delivered per probiotic dose are clinically negligible. Bioavailability context: the strain demonstrates documented gastric acid and bile salt tolerance, with survival rates through the GI tract sufficient to achieve live colonization of the colon, a key factor distinguishing it from many probiotic strains. No significant protein, fat, or dietary fiber content is delivered at standard probiotic doses.

## Dosage & Preparation

Clinically studied dose: 10^10 CFU/day (10 billion colony-forming units), typically as two 5×10^9 CFU capsules daily. Available in fermented milk, capsules, or powder forms. Standard treatment duration in IBS trials: 4-8 weeks. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Lactobacillus plantarum 299v is generally recognized as safe, with adverse events in clinical trials limited to mild, transient gastrointestinal symptoms such as bloating and flatulence that typically resolve within the first week of use. Individuals who are immunocompromised, have short bowel syndrome, or have central venous catheters should consult a physician before use, as rare cases of bacteremia have been reported with [probiotic](/ingredients/condition/gut-health) strains in high-risk populations. No clinically significant drug interactions have been formally established, though concurrent use with broad-spectrum antibiotics will reduce colonization efficacy and should be temporally separated by at least two hours. Safety data in pregnancy and lactation are limited; while the strain is considered low-risk, pregnant individuals should seek medical guidance before supplementation.

## Scientific Research

Multiple randomized controlled trials support L. plantarum 299v for IBS symptom relief, with the largest multicenter RCT (n=214, PMID: 22912552) showing significant reductions in pain and bloating over 4 weeks. However, one hospital-based RCT (PMID: 25194614) found no benefit over placebo at 8 weeks, possibly due to large placebo effects. Additional trials demonstrate benefits for colonic fermentation (PMID: 12452404), C. difficile-associated diarrhea (PMID: 12953945), and vascular function (PMID: 30355158).

## Historical & Cultural Context

L. plantarum 299v has no traditional or historical use, as it is a patented strain clinically developed in the 1990s. Unlike many [probiotic](/ingredients/condition/gut-health)s with roots in traditional fermented foods, this specific strain was isolated directly from human intestinal mucosa for therapeutic purposes.

## Synergistic Combinations

Prebiotics (FOS/GOS), [Digestive enzyme](/ingredients/condition/gut-health)s, Peppermint oil, Glutamine, Slippery elm

## Frequently Asked Questions

### What is the recommended dosage of Lactobacillus plantarum 299v for IBS?

Clinical trials demonstrating IBS benefit have most commonly used doses of 10 billion CFU (10^10 CFU) daily, taken once per day with or before a meal. The pivotal 214-patient RCT used this dose over four weeks and achieved a 45.2% reduction in pain severity, suggesting this as the evidence-based starting point for supplementation.

### How long does Lactobacillus plantarum 299v take to work for IBS symptoms?

In clinical trials, statistically significant improvements in abdominal pain and bloating were observed within two to four weeks of daily supplementation at 10 billion CFU. Some patients report early symptom changes within the first week, but the full therapeutic effect generally requires consistent use for at least one complete month.

### Is Lactobacillus plantarum 299v the same as Lactobacillus plantarum 299?

Lactobacillus plantarum 299v (LP299V) and Lactobacillus plantarum 299 are closely related but distinct sub-strains; 299v carries the trademark designation used by Probi AB and is the strain used in the majority of published human clinical trials. While both share the same species and mannose-adhesin properties, efficacy data from 299v trials should not be automatically extrapolated to uncharacterized plantarum strains sold generically.

### Can Lactobacillus plantarum 299v help with bloating?

Yes, bloating is a secondary endpoint in multiple IBS trials of LP299V, with significant reductions reported alongside pain relief at the 10 billion CFU daily dose. The mechanism involves suppression of gas-producing pathogenic bacteria through competitive exclusion and enhancement of intestinal motility via modulation of serotonin signaling pathways in enteric neurons.

### Does Lactobacillus plantarum 299v survive stomach acid?

LP299V has demonstrated superior acid and bile tolerance compared to many other Lactobacillus strains in in vitro studies, with viable cell counts remaining sufficient for colonization after gastric transit at physiological pH levels between 2.0 and 3.0. Its mannose-specific adhesins then allow it to anchor to intestinal mucosa rather than being flushed through, which is a key reason this strain has shown consistent clinical efficacy in human trials.

### What clinical evidence supports Lactobacillus plantarum 299 for IBS pain relief?

A 214-patient randomized controlled trial demonstrated that Lactobacillus plantarum 299 reduced IBS pain severity by 45.2% compared to 23.3% in the placebo group, with 78.1% of patients rating its efficacy as good or excellent. A separate 40-patient RCT showed even more dramatic results, with 100% of treated patients achieving complete pain resolution versus only 45% in the placebo group. This strong clinical evidence positions it as one of the most well-researched probiotic strains for IBS-related abdominal pain.

### Who should consider taking Lactobacillus plantarum 299 supplements?

Lactobacillus plantarum 299 is most beneficial for individuals with irritable bowel syndrome (IBS), particularly those experiencing abdominal pain, bloating, and excessive colonic fermentation. The clinical research is strongest for IBS patients seeking a well-evidenced probiotic intervention, though it may also benefit those with general digestive discomfort related to dysbiosis. Individuals who have not responded adequately to dietary modifications alone may be good candidates for this strain.

### Is Lactobacillus plantarum 299 safe to use alongside other supplements or medications?

Probiotics like Lactobacillus plantarum 299 are generally well-tolerated, though they should be taken separately from antibiotics (which can kill the beneficial bacteria) and ideally spaced 2+ hours apart from antimicrobial herbs or high-dose antibiotic therapy. Those with severe immunocompromise or serious underlying conditions should consult a healthcare provider before use. Most users can safely combine it with standard vitamins, minerals, and digestive enzymes without concern.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*